# A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

> **NCT00401479** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Irritable Bowel Syndrome (IBS)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Solabegron (GW427353)

## Key facts

- **NCT ID:** NCT00401479
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2008-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401479, "A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00401479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*